Recent Updates
Recently added Catalysts
GLUE

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Tuesday, January 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Price reaction · baseline $14.4 (2026-01-05 close) · hit after-hours · 3 other GLUE headline(s) in the window, move may be shared
day 0 close
+11.2%
day 1
+61.7%
day 3 · peak
+68.6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)

Full Press Release Details

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results.
ShareAdd on Google
Tags: GLUE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 6, 2026

Biotech snapshot

Cash runway
$621M liquidity · $15M/mo burn
~41 mo
Minimal dilution risk
Lead asset
MRT-2359Phase 2
Castration-Resistant Prostate Cancer (CRPC) →

Catalyst track record

+67%
best trade around GLUE's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for GLUE.

See every catalyst's timing & PoA →